GSK Marketing Planning | March 31 2013 | Calvin Cheung‚ Hussain Al Katib‚ Manpreet Budwal‚ Sandra Okechukwu | SOSTAC Review based on GlaxoSmithKline | Content Table of Contents 1.0 Introduction2 2.0 Situation Analysis3 2.1 PESTEL Analysis3 2.2 SWOT Analysis4 2.3 Boston Matrix5 2.4 Porter’s Five Forces Analysis6 3.0 Objectives8 4.0 Strategy9 4.1 Product9 4.2 Price9 4.3 Promotion9 4.4 Place10 4.5 Person10 4.6 Process10 4.7 Physical Evidence10 5.0 Tactics11 6.0 Action Plan12
Premium Marketing
CASE STUDY Presentation Outline: Background Case Summary What is ‘crisis management’? Strategic Phase Reactive Phase Image Restoration Lessons Learnt Background: GlaxoSmithKline (GSK) is a British multinational pharmaceutical and consumer healthcare company that operates in over 100 countries. They have an extensive portfolio of products for major disease areas including asthma‚ cancer‚ infection‚ diabetes and digestive conditions Some products they produce that you might be familiar
Free Crisis management Management
industry. This report gives insight on the analysis of the strategies used by GlaxoSmithKline (vaccines and medicine business unit) to be able to sustain its performance in the pharmaceutical industry. This report applies PESTLE model‚ Porter’s five-force model‚ and Value chain analysis as well as the SWOT analysis tools environment facing the company. The reports assess performance of GSK Company amid the economic downturns. Based on the findings‚ GSK has been able to harness its potential‚ in efforts
Premium Pharmaceutical industry Strategic management Marketing
name] GSK – Successful Internal Innovation Question 1 Based on GSK’s past performance‚ what do you believe are the critical implementation issues for GSK with regards to internal innovation? Figure 4‚ 2‚ pg 132‚ The management of technology and innovation (White & Brighton) GSK key reason of success lies in its continuous radical change‚ by constantly inventing new drugs. Critical to the implementation issues of its internal innovation are raised below: Leadership GSK leadership
Premium Control system Control engineering Invention
Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products‚ competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources Financial review 2009 Risk factors Governance and remuneration Our Board Our Corporate Executive Team Governance and policy Dialogue with shareholders
Premium Vaccine Rate of return Clinical trial
considered blockbusters * The company was lacking a distinctive identity * Keeping the stakeholders tolerant * Organizing 15000 scientists worldwide for efficient yet effective research All these issues can be narrowed down into four broad strategic issues: * Cost Reduction * Breaking up the pipeline * Effectiveness of R & D * Economies of Scale Cost reduction Top executives anticipated the combined company would save an annualised £1 billion after 3 years. These
Premium
Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
PROJECT REPORT ON WORKING CAPITAL MANAGEMENT WITH SPECIAL EMPHASIS ON VARIOUS TECHNIQUES OF INVENTORY CONTROL [pic] A training report submitted in partial fulfillment of the requirement for the degree Of MASTERS OF BUSINESS ADMINISTRATION (2010-2012) SUBMITTED TO: SUBMITTED BY:
Premium Inventory Financial ratio
Answer 2 …… Glaxosmithkline (GSK )‚ a research and development firm seeking to be excel in internal innovation through research on eight therapy areas- biopharmaceuticals‚ immune-inflammation‚ infectious diseases‚ metabolic pathways‚ neuroscience‚ oncology‚ ophthalmology and respiratory. To address these areas the firm in 2008 created 70 Discovery Performance Unit (DPUs) for future growth of the company. These 70 DPUs can affect the implementation effort in following ways to achieve success in
Premium Research Control theory Innovation
1) Product markets and geographic markets in which GSK is present GSK’s core mission is to “improve the quality of human life by enabling people to do more‚ feel better and live longer”. To achieve this mission‚ they operate in three main areas of businesses: the Pharmaceuticals (£18 Bn in 2012‚ or 68% of their revenues)‚ the Vaccines (£3.3 Bn‚ or 11% or their revenues) and the Consumer Healthcare (£5.1 Bn‚ or 19% of their revenues). In particular‚ the Pharmaceuticals cover medicines to treat a broad
Premium Medicine Pharmacology Food and Drug Administration